GlassScriptPhysician profile
Tiffany Jones
NPI 1659700136
$99,045.60
in general payments reported to CMS, 2019-2025
32 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $25K · 2023: $22K · 2024: $25K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Travel and Lodging: $6,409 · Consulting Fee: $6,205 · Food and Beverage: $4,795 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,196.00 |
| Travel and Lodging | $6,408.93 |
| Consulting Fee | $6,205.00 |
| Food and Beverage | $4,794.87 |
| Education | $141.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $45,253.42 | 2021-2025 | Tagrisso, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $23,211.46 | 2021-2025 | Opdivo, Krazati |
| Pfizer INC. | $16,436.37 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $5,102.92 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $3,326.44 | 2022-2025 | Opdivo |
| Array Biopharma INC | $1,980.00 | 2022-2023 | Braftovi |
| Janssen Scientific Affairs, LLC | $1,125.00 | 2023-2024 | Rybrevant, Erleada |
| Astellas Pharma US INC | $303.59 | 2023-2024 | Padcev, Xospata, Vyloy |
| Amgen INC. | $274.29 | 2023-2024 | Lumakras |
| Seagen INC. | $238.18 | 2022-2023 | Tukysa |
| Novartis Pharmaceuticals Corporation | $205.65 | 2022-2025 | |
| Abbvie INC. | $204.66 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $153.89 | 2022-2023 | |
| Genentech USA, INC. | $140.90 | 2021-2024 | Tecentriq, Alecensa |
| Janssen Biotech, INC. | $140.55 | 2022-2025 | Rybrevant |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $124.60 | 2024-2025 | Trodelvy |
| Pharmacosmos Therapeutics INC. | $107.67 | 2025 | Monoferric |
| Kite Pharma, INC. | $96.85 | 2021 | |
| Tempus Ai, INC | $94.66 | 2025 | Xt Cdx |
| Incyte Corporation | $90.31 | 2021 | |
| Daiichi Sankyo INC. | $70.12 | 2024-2025 | Enhertu, Datroway |
| Lilly USA, LLC | $67.36 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $60.21 | 2022 | |
| Sanofi-Aventis U.S. LLC | $41.99 | 2024 | |
| Eisai INC. | $37.87 | 2025 | |
| Glaxosmithkline, LLC. | $36.36 | 2024-2025 | Zejula, Jemperli |
| Immunocore Limited | $31.65 | 2025 | Kimmtrak |
| Mirati Therapeutics, INC. | $23.00 | 2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $20.89 | 2025 | Onivyde |
| Adaptive Biotechnologies Corporation | $15.67 | 2025 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $15.04 | 2024 | Libtayo |
| Genzyme Corporation | $14.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.